环氧化酶-2抑制剂对非小细胞肺癌抗肿瘤作用机制的研究进展

肺癌目前位于全世界癌症死因的首位，约占全部恶性肿瘤的19％。每年约有超过100万人死于肺癌，严重威胁着人类的健康和生命。其中，非小细胞肺癌约占80％～85％。研究显示环氧化酶-2（cycl00xygenase-2，COX-2）在非小细胞肺癌组织中表达上调，并且与肿瘤细胞的增殖、侵袭和远处转移有关。近年来COX-2抑制剂在非小细胞肺癌治疗中的作用日益受到关注。特异性COX～2抑制剂（尼美舒利、塞来昔布、罗非昔布、NS398等）和非特异性COX-2抑制剂（吲哚美辛、布洛芬等）对非小细胞肺癌均有抗肿瘤作用，可增加非小细胞肺癌化疗及放疗的敏感性。实验研究表明COX-2抑制剂可抑制非小细胞肺癌细胞的增殖，诱导细胞的凋亡，抑制肿瘤新生血管的生成，抑制肿瘤远处转移等。国外临床研究表明COX-2抑制剂可提高化疗药物的临床疗效，并减弱化疗不良反应。COX-2抑制剂显著的抗肿瘤作用为非小细胞肺癌的治疗带来了新的曙光。

Studies on anti-tumor mechanism of cyciooxygenase-2 inhibitor in non-small cell lung cancer

Lung cancer is the leading cause of cancer death in the world now,accounting for about 19% of all malignant tumors. More than one million people die from lung cancer each year, which has been a serious threat to human health and life. Non-small cell lung cancer accounts for 80%-85%. Studies have shown that up-regulation of cyclooxygenase-2 （COX-2） expression in non small cell lung cancer, which is correlated with the tumor cell proliferation,invasion, and metastasis. In recent years, the role of COX-2 inhibitors in the treatment of non-small cell lung cancer has been paid more and more attention. Both specific COX-2 inhibitors （nimesulide, celecoxib, rofecoxib, and NS398） and nonspecific COX-2 inhibitors （indomethacin,ibuprofen） have the anti-tumor effect on non-small cell lung cancer, and also can increase the sensitivity of chemotherapy and radiotherapy. Experimental studies have shown that COX-2 inhibitors may inhibit tumor cell proliferation, induce apoptosis, inhibit tumor angiogenesis and metastasis. Clinical studies abroad have shown that COX-2 inhibitors may enhance the clinical outcomes of chemotherady,and reduce the side effects. All these have brought a new dawn for the treatment of non- small cell lung cancer.